Skip to main content

GALDY · Galderma Group AG · Metrics

Track GALDY — free
$46.57 -0.84 (-1.77%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Market Cap
$55.28B
Shares
1.17B
Volume · Nov 6 127.35K Avg daily vol (3M) 207.59K

GALDY metrics

40 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$46.57
Market cap
$55.28B

Price action

23 metrics
Price change (1W)
+3.1%
Price change (30D)
+21.4%
Price change (3M)
+8.0%
Price change (6M)
+10.1%
Price change (YTD)
+14.4%
Price change (1Y)
+31.5%
Trailing year
Price change (5Y)
—
52-week high
$47.81
52-week low
$35.68
Change from 52-week high
-0.8%
Change from 52-week low
+32.9%
Annualized volatility
32.0%
Annualized volatility (3M)
31.5%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
70.0
Price vs SMA 50
+15.2%
Price vs SMA 200
+16.0%
Avg volume (3M)
206,549
Relative volume
1.2
Average dollar volume
$8.43M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.17B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.2%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.09
Dividend growth YoY
+144.3%
Dividend growth streak
—
Last ex-dividend
2026-04-27

Earnings calendar

2 metrics
Next earnings
2027-02-25
Last earnings
2026-10-22

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
5
13F filer change QoQ
+2
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+38.8%
Holder tenure
3.8
Price vs estimated holder cost
+18.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2021390 CUSIP 36321W105 13F (30d) 5 filings 5 filers Visit website Investor relations